Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company’s guidance may be getting in the way a bit. The drug giant…
Jim Cramer has touted several DJIA upside calls in 2012, but on Monday’s MAD MONEY on CNBC Cramer touted Merck & Company, Inc. (NYSE: MRK) as the great pharma outfit with what may…
The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp blows to…
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of players in the sector. With Merck & Co. (NYSE: MRK) driving further…
US markets opened up slightly this morning and have maintained a slight positive tone for most of the day. Today marks the unofficial beginning of another earnings season, with Alcoa kicking things…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Monday morning. Akamai Technologies, Inc. (NASDAQ: AKAM) Cut to Sell from…
For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like Pfizer Inc.…
As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow Jones Industrial Average price targets from Wall Street analysts to come up…
The lineup of the Dogs of the Dow, simply the ten highest dividend yield stocks of the thirty Dow Jones Industrial Average components, appears to be undergoing a bit of change for…
We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks and months ahead. Among those we expect to raise the dividend is…
AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to approve it…
Jon C. Ogg Dividends are still rising and equity and income investors should expect more of the same for 2012. The Walt Disney Company (NYSE: DIS) joined in on the dividend hike brigade with another dividend…
China’s factory activity reaches a 32-month low. (Reuters) Merck (NYSE: MRK) pays $950 million to settle Vioxx charges brought by the government. (Reuters) FCC head wants more examination of the AT&T (NYSE:…
Merck (NYSE: MRK) will pay $950 million to settle criminal and civil charges that it inappropriately promoted use of Vioxx, according to The Justice Department
Douglas A. McIntyre It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie…
